QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy”